Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
Executive Summary
Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.